{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:51Z","timestamp":1790516151977,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. The primary outcome measure was the overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks and best response during treatment. Key secondary objectives were characterization of toxicity and determination of progression-free survival (PFS) and overall survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with objective responses and results in prolonged disease control. Although the initial primary outcome objective of the study was not met, the observation of objective responses in heavily pretreated patients coupled with a favorable PFS suggests that ibrutinib may be beneficial in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01841723.<\/jats:p>","DOI":"10.1182\/blood.2020009688","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:56:33Z","timestamp":1616460993000},"page":"3473-3483","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Phase 2 study of ibrutinib in classic and variant hairy cell leukemia"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"first","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-1766","authenticated-orcid":false,"given":"Leslie A.","family":"Andritsos","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-3828","authenticated-orcid":false,"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Anghelina","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Call","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-7884","authenticated-orcid":false,"given":"Anees","family":"Dauki","sequence":"additional","affiliation":[{"name":"College of Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey R.","family":"James","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lucas","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apollinaire","family":"Ngankeu","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Phelps","sequence":"additional","affiliation":[{"name":"College of Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-7533","authenticated-orcid":false,"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2021062415255173900_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2021062415255173900_B2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"},{"issue":"11","key":"2021062415255173900_B3","first-page":"886","article-title":"Leukaemic reticuloendotheliosis","volume":"74","author":"Gosselin","year":"1956","journal-title":"Can Med Assoc J"},{"issue":"20","key":"2021062415255173900_B4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2021062415255173900_B5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2021062415255173900_B6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","article-title":"The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma","volume":"158","author":"Hockley","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2021062415255173900_B7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0145-2126(80)90066-1","article-title":"A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia","volume":"4","author":"Cawley","year":"1980","journal-title":"Leuk Res"},{"issue":"suppl 2","key":"2021062415255173900_B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2021062415255173900_B9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience","volume":"106","author":"Chadha","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2021062415255173900_B10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"18","key":"2021062415255173900_B11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2021062415255173900_B12","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2021062415255173900_B13","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2021062415255173900_B14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2021062415255173900_B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2021062415255173900_B16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"2021062415255173900_B17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2021062415255173900_B18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"29","key":"2021062415255173900_B19","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2021062415255173900_B20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"2021062415255173900_B21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jpba.2015.10.033","article-title":"Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies","volume":"118","author":"Rood","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2021062415255173900_B22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12185-015-1900-3","article-title":"Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed\/refractory B cell malignancies","volume":"103","author":"Tobinai","year":"2016","journal-title":"Int J Hematol"},{"issue":"2","key":"2021062415255173900_B23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12867","article-title":"The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"},{"issue":"15","key":"2021062415255173900_B24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/sj.onc.1206398","article-title":"Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways","volume":"22","author":"Kamiguti","year":"2003","journal-title":"Oncogene"},{"issue":"24","key":"2021062415255173900_B25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"2021062415255173900_B26","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2021062415255173900_B27","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2021062415255173900_B28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ajh.2830160410","article-title":"Infectious complications in 127 patients with hairy cell leukemia","volume":"16","author":"Golomb","year":"1984","journal-title":"Am J Hematol"},{"issue":"19","key":"2021062415255173900_B29","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2021062415255173900_B30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/10428194.2018.1512710","article-title":"Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib","volume":"60","author":"Barrientos","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2021062415255173900_B31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2021062415255173900_B32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"issue":"16","key":"2021062415255173900_B33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"2021062415255173900_B34","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V80.9.2203.2203","article-title":"A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia","volume":"80","author":"Tallman","year":"1992","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/25\/3473\/1810718\/bloodbld2020009688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/25\/3473\/1810718\/bloodbld2020009688.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T15:26:45Z","timestamp":1624548405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/25\/3473\/475585\/Phase-2-study-of-ibrutinib-in-classic-and-variant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":34,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2021,6,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009688","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]}}}